Data Sheet (Cat.No.T5432)

TargetMol
YOUR TARGET MOLECULES

Eganelisib

Chemical Properties



CAS No. : 1693758-51-8

Formula: C30H24N8O2

Molecular Weight: 528.56

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Eganelisib (IPI-549) is an inhibitor of PI3Kγ (IC50 = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively)
Targets(IC50)	PI3K
In vitro	IPI-549 sensitizes doxorubicin-resistant SW620/Ad300 cells to P-glycoprotein (P-gp) substrates, such as paclitaxel (IC50s = 710 and 6.7 nM for paclitaxel alone and in combination with IPI-549, respectively), and increases the level of intracellular paclitaxel in SW620/Ad300 cells[1].
In vivo	IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo[2].
Animal Research	SW620 (4 X 10^6) and SW620/Ad300 (5 X 10^6) cells were injected subcutaneously at the flank near the armpits of athymic nude mice.?When the subcutaneous tumors were approximately 0.5 x 0.5 cm in size (day 0), the mice were randomized into four treatment groups.?The vehicle used to deliver the IPI-549 and paclitaxel by intraperitoneal (i.p.) injection was ethanol/Cremophor ELP/saline (10%/10%/80%).?Group one received the vehicle only;?group two received vehicle plus 3 mg/kg IPI-549;?group three received vehicle plus 15 mg/kg paclitaxel;?group four, the combination group, received vehicle plus 3 mg/kg IPI-549 one h prior to administration of vehicle plus 15 mg/kg paclitaxel.?The drug doses were administered every 3 days with a total of 4 doses.?Tumor volume was measured using calipers, and body weights were recorded prior to each dosing.

Solubility Information

Solubility	DMSO: 15 mg/mL (28.38 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8919 mL	9.4597 mL	18.9193 mL
5 mM	0.3784 mL	1.8919 mL	3.7839 mL
10 mM	0.1892 mL	0.946 mL	1.8919 mL
50 mM	0.0378 mL	0.1892 mL	0.3784 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

De Vera AA1, Gupta P.et al.Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1) -mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.Cancer Lett. 2019 Feb 1;442:91-103